Molecular approaches to developmental malformations using analogous forms of valproic acid
Akinobu Okada1, Michio Fujiwara
1Drug Safety Research Laboratories, Astellas Pharma, Yodogawa-ku, Osaka, Japan. akinobu.okada@jp.astellas.com
Congenital Anomalies
|May 31, 2006
Summary
Valproic acid (VPA) causes birth defects. This study used gene expression analysis in mouse embryos to identify genes and molecular pathways involved in VPA teratogenicity, aiding in safer drug development.
Area of Science:
- Developmental Biology
- Toxicology
- Genomics
Background:
- Valproic acid (VPA) is a known teratogen with established risks in human and experimental studies.
- VPA serves as a model for investigating chemical structure-teratogenicity relationships.
- Understanding VPA's molecular mechanisms is crucial for predicting and mitigating developmental toxicity.
Purpose of the Study:
- To identify genes and molecular pathways underlying VPA teratogenicity in mouse embryonic neural tube and axial skeleton.
- To utilize teratogenomics for a genome-wide understanding of VPA's developmental effects.
- To provide insights for developing safer pharmaceutical alternatives.
Main Methods:
- Utilized DNA microarray (GeneChip system) and quantitative real-time polymerase chain reaction (qPCR).
- Employed low teratogenic VPA analogs as comparative controls.
- Analyzed gene expression changes in mouse embryos exposed to VPA during critical developmental periods.
Main Results:
- Identified specific genes and altered expression patterns associated with VPA exposure.
- Revealed molecular mechanisms by which VPA disrupts neural tube and axial skeleton development.
- Established a gene expression signature for VPA teratogenicity.
Conclusions:
- VPA-induced gene expression changes offer critical insights into its teratogenic mechanisms.
- This research supports the development of safer medicines by understanding VPA's molecular targets.
- Teratogenomics provides a powerful approach to assess chemical developmental toxicity.
Related Concept Videos
01:07Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
01:16In-vitro Mutagenesis
To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.